Capstone Holding

Capstone Holding FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Capstone Holding (CAPS) as of Oct 27, 2026 is 21.54 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -144.40 % — a change of -114.91% (higher).

FCF Conversion

21.54 %

YoY

-114.91%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Capstone Holding is 2025 21.54 % . FCF Conversion Rate (FCF/EBITDA) of Capstone Holding was 2024 -144.40 % . It decreases by -114.91% higher compared to the previous year.

The Capstone Holding FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-17.37 USD
Jan 1, 2019
80.99 USD
Jan 1, 2020
6.11 USD
Jan 1, 2021
65.06 USD
Jan 1, 2022
-132.31 USD
Jan 1, 2023
-37.76 USD
Jan 1, 2024
-144.40 USD
Jan 1, 2025
21.54 USD
The Capstone Holding FCF Conversion history
YEARFCF ConversionYoY
21.54 %-114.91%
-144.40 %+282.43%
-37.76 %-71.46%
-132.31 %-303.37%
65.06 %+964.48%
6.11 %-92.45%
80.99 %-566.33%
-17.37 %-119.53%
88.95 %-53.16%
189.89 %+144.40%
77.70 %-20.92%
98.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Capstone Holding Stock analysis

What does Capstone Holding do? Capstone Therapeutics Corp. is a biopharmaceutical company focused on the development of innovative therapeutic solutions for unmet medical needs. The company was founded in 1987 and is headquartered in Tempe, Arizona. It began as a research project at Arizona State University, eventually leading to the founding of the company. Capstone Therapeutics utilizes its technology platform in peptide chemistry, cell biology, and pharmacology to develop therapies for diseases with limited treatment options. Its core business includes developing medications for neurodegenerative diseases like Alzheimer's and oncological diseases with no effective treatment options. The company collaborates with other industry leaders in biotechnology and holds a strong intellectual property position. Capstone Therapeutics aims to improve the lives of individuals with serious illnesses through its innovative products and strategic approach. Capstone Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Capstone Holding stock

FCF Conversion Rate (FCF/EBITDA) of Capstone Holding is 21.54 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Capstone Holding changed from -144.40 % to 21.54 %, representing a -114.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Capstone Holding since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Capstone Holding with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Capstone Holding

All Key Metrics — Capstone Holding